Please Support “Team ASPS” 2022 PMC Bike Ride at The PMC in Search for Cure
Dear Friends, On Saturday and Sunday August 6 and 7th, 2022, Team ASPS will ride for the 19th time the Pan-Massachusetts Challenge (PMC) bike ride. This year our team includes six riders! We are raising donations and riding to find a cure for Alveolar Soft Part Sarcoma (ASPS). ASPS is a rare cancer that tends […]
Please donate to support Team ASPS efforts to find a cure for Alveolar Soft Part Sarcoma: 2021 PMC bike ride
Update:Â On August the 8th, 2021, Team ASPS Completed the PMC Bike Ride of 100 Miles, the Fundraising to support ASPS Research at the Dana Farber Cancer Institute in Boston is On-going. Please donate, and read more below”. Dear Friends, On August 7-8th, Team ASPS will ride for the 18th time on the Pan-Massachusetts Challenge […]
Phase 2 Clinical Trial for Alveolar Soft Part Sarcoma Patients: Testing Atezolizumab, A Study by the NCI
Dear ASPS community, please read the recent update of this clinical trial from September 2020: This is a Phase II clinical study testing the ability of the anti-PD-L1 antibody, Atezolizumab, in treating patients with ASPS that has spread to other parts of the body and cannot be removed by surgery. The FDA granted Breakthrough Therapy Designation […]
2019 Progress Report on Alveolar Soft Part Sarcoma – American Society of Clinical Oncology (ASCO) annual meeting
We selected to highlight 3 studies that were presented this year at the ASCO conference: 1. Treatment of ASPS with anlotinib (a new oral tyrosine kinase inhibitor therapy), Clinical trial information: NCT02449343 2. Combination treatment of ASPS with NKTR214 (immune modulator) and nivolumab (immune checkpoint inhibitor), Clinical trial information: NCT03282344 3. Successful generation of patient-derived xenografts and cell […]
Progress Reports on Alveolar Soft Part Sarcoma from the ASCO 2018 Meeting
The American Society of Clinical Oncology (ASCO) annual meeting took place this year in Chicago between June 1-5, 2018 Here are eight Alveolar Soft Part Sarcoma (ASPS) related abstracts from the meeting. Of these, seven describing results of clinical trials with the following treatments: Phase III of Anlotinib Phase II trial of Axitinib plus pembrolizumab […]
Update on Alveolar Soft Part Sarcoma Clinical and Preclinical Studies as Presented at the Annual Meeting of CTOS in November 8-11, 2017
Below are summaries of three clinical studies and one preclinical study on Alveolar Soft Part Sarcoma as were presented at the 2017 annual meeting of the “Connective Tissue Oncology Society†(CTOS) in November 8-11. Please click the titles of each one of the 3 clinical studies to read more information on the “clinical Trials.gov†website. […]
New ASPS Trial: A​​PROMISS – A Phase III Trial of Anlotinib for Patients with Alveolar Soft Part Sarcoma and Other Sarcomas
OPEN NOW: ​​​APROMISS – A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma​​ Sponsored by: ​Advenchen Laboratories, LLC. ClinicalTrials.gov Identifier: ​NCT03016819 ​Anlotinib (AL3818), a tyrosine kinase inhibitor, is an investigational drug being evaluated in the treatment of ​Alveolar ​Soft ​Part ​Sarcoma​ […]
The 13th PMC Bike Ride of “Team ASPS†and the Upcoming 14th Ride: Please Support Our Efforts to Find a Cure for ASPS
On August 6 – 7 2016, “Team ASPS†participated for the 13th time in the Pan-Massachusetts Challenge (PMC) bike ride. This bike-a-thon crosses Massachusetts to raise money for cancer research and treatment at the Dana-Farber Cancer Institute (DFCI) in Boston. Our team rode 163 miles and raised $49,117 specifically dedicated for finding a cure for ASPS. Registration […]
Alveolar Soft Part Sarcoma Day of Learning at the University of Miami – September 23
Dr. Breelyn A. Wilky, MD., Assistant Professor – Sarcoma Program, Sylvester Comprehensive Cancer Center from the Division of Hematology/Oncology Leonard M. Miller School of Medicine at the University of Miami has organized an ASPS open day of learning. The open day will take place on Friday, September 23, 2016 7:30am-5:00pm. The event is open to patients, families, […]
Anlotinib Shows Efficacy in ASPS Patients in Phase II Study in China
A presentation is the recent annual meeting of the American Society of Clinical Oncology (ASCO) conference in Chicago highlighted the new drug Anlotinib and its efficacy in treating Alveolar Soft Part Sarcoma patients. Anlotinib is a new receptor tyrosine kinase inhibitor, currently in phase II clinical trials in China. Patients with different types of soft […]